These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

791 related articles for article (PubMed ID: 23348816)

  • 1. Nearly complete elimination of the 7-valent pneumococcal conjugate vaccine serotypes in Tennessee.
    Halasa NB; Grijalva CG; Arbogast PG; Talbot TR; Craig AS; Griffin MR; Schaffner W
    Pediatr Infect Dis J; 2013 Jun; 32(6):604-9. PubMed ID: 23348816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.
    Steens A; Bergsaker MA; Aaberge IS; Rønning K; Vestrheim DF
    Vaccine; 2013 Dec; 31(52):6232-8. PubMed ID: 24176490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of antibiotic-nonsusceptible Streptococcus pneumoniae with conjugate vaccines.
    Hampton LM; Farley MM; Schaffner W; Thomas A; Reingold A; Harrison LH; Lynfield R; Bennett NM; Petit S; Gershman K; Baumbach J; Beall B; Jorgensen J; Glennen A; Zell ER; Moore M
    J Infect Dis; 2012 Feb; 205(3):401-11. PubMed ID: 22158567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of pneumococcal conjugate vaccines on burden of invasive pneumococcal disease and serotype distribution of Streptococcus pneumoniae isolates: an overview from Kuwait.
    Mokaddas E; Albert MJ
    Vaccine; 2012 Dec; 30 Suppl 6():G37-40. PubMed ID: 23228356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduction in high rates of antibiotic-nonsusceptible invasive pneumococcal disease in tennessee after introduction of the pneumococcal conjugate vaccine.
    Talbot TR; Poehling KA; Hartert TV; Arbogast PG; Halasa NB; Mitchel E; Schaffner W; Craig AS; Edwards KM; Griffin MR
    Clin Infect Dis; 2004 Sep; 39(5):641-8. PubMed ID: 15356776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changing epidemiology of invasive pneumococcal disease among White Mountain Apache persons in the era of the pneumococcal conjugate vaccine.
    Lacapa R; Bliss SJ; Larzelere-Hinton F; Eagle KJ; McGinty DJ; Parkinson AJ; Santosham M; Craig MJ; O'Brien KL
    Clin Infect Dis; 2008 Aug; 47(4):476-84. PubMed ID: 18627249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Invasive pneumococcal disease a decade after pneumococcal conjugate vaccine use in an American Indian population at high risk for disease.
    Weatherholtz R; Millar EV; Moulton LH; Reid R; Rudolph K; Santosham M; O'Brien KL
    Clin Infect Dis; 2010 May; 50(9):1238-46. PubMed ID: 20367225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changing serotypes causing childhood invasive pneumococcal disease: Massachusetts, 2001-2007.
    Hsu KK; Shea KM; Stevenson AE; Pelton SI;
    Pediatr Infect Dis J; 2010 Apr; 29(4):289-93. PubMed ID: 19935447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibiotic resistance and serotype distribution of invasive pneumococcal diseases before and after introduction of pneumococcal conjugate vaccine in the Kingdom of Saudi Arabia (KSA).
    Shibl AM; Memish ZA; Al-Kattan KM
    Vaccine; 2012 Dec; 30 Suppl 6():G32-6. PubMed ID: 23228355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surveillance for invasive pneumococcal disease during 2000-2005 in a population of children who received 7-valent pneumococcal conjugate vaccine.
    Black S; France EK; Isaacman D; Bracken L; Lewis E; Hansen J; Fireman B; Austrian R; Graepel J; Gray S; Klein NP
    Pediatr Infect Dis J; 2007 Sep; 26(9):771-7. PubMed ID: 17721369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolving picture of invasive pneumococcal disease in massachusetts children: a comparison of disease in 2007-2009 with earlier periods.
    Yildirim I; Stevenson A; Hsu KK; Pelton SI
    Pediatr Infect Dis J; 2012 Oct; 31(10):1016-21. PubMed ID: 22673142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidemiologic characteristics, serotypes, and antimicrobial susceptibilities of invasive Streptococcus pneumoniae isolates in a nationwide surveillance study in Lebanon.
    Hanna-Wakim R; Chehab H; Mahfouz I; Nassar F; Baroud M; Shehab M; Pimentel G; Wasfy M; House B; Araj G; Matar G; Dbaibo G;
    Vaccine; 2012 Dec; 30 Suppl 6():G11-7. PubMed ID: 23228352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines.
    Isaacman DJ; McIntosh ED; Reinert RR
    Int J Infect Dis; 2010 Mar; 14(3):e197-209. PubMed ID: 19700359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibiotic susceptibility rates of invasive pneumococci before and after the introduction of pneumococcal conjugate vaccination in Germany.
    Imöhl M; Reinert RR; van der Linden M
    Int J Med Microbiol; 2015 Oct; 305(7):776-83. PubMed ID: 26324014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pneumococcal carriage in children and adults two years after introduction of the thirteen valent pneumococcal conjugate vaccine in England.
    van Hoek AJ; Sheppard CL; Andrews NJ; Waight PA; Slack MP; Harrison TG; Ladhani SN; Miller E
    Vaccine; 2014 Jul; 32(34):4349-55. PubMed ID: 24657717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changing epidemiology of invasive pneumococcal disease in Canada, 1998-2007: update from the Calgary-area Streptococcus pneumoniae research (CASPER) study.
    Kellner JD; Vanderkooi OG; MacDonald J; Church DL; Tyrrell GJ; Scheifele DW
    Clin Infect Dis; 2009 Jul; 49(2):205-12. PubMed ID: 19508165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine.
    Pilishvili T; Lexau C; Farley MM; Hadler J; Harrison LH; Bennett NM; Reingold A; Thomas A; Schaffner W; Craig AS; Smith PJ; Beall BW; Whitney CG; Moore MR;
    J Infect Dis; 2010 Jan; 201(1):32-41. PubMed ID: 19947881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of Antibiotic-Nonsusceptible Invasive Pneumococcal Disease With the 13-Valent Pneumococcal Conjugate Vaccine.
    Tomczyk S; Lynfield R; Schaffner W; Reingold A; Miller L; Petit S; Holtzman C; Zansky SM; Thomas A; Baumbach J; Harrison LH; Farley MM; Beall B; McGee L; Gierke R; Pondo T; Kim L
    Clin Infect Dis; 2016 May; 62(9):1119-25. PubMed ID: 26908787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine.
    Muñoz-Almagro C; Jordan I; Gene A; Latorre C; Garcia-Garcia JJ; Pallares R
    Clin Infect Dis; 2008 Jan; 46(2):174-82. PubMed ID: 18171247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Geographic variation in invasive pneumococcal disease following pneumococcal conjugate vaccine introduction in the United States.
    Rosen JB; Thomas AR; Lexau CA; Reingold A; Hadler JL; Harrison LH; Bennett NM; Schaffner W; Farley MM; Beall BW; Moore MR;
    Clin Infect Dis; 2011 Jul; 53(2):137-43. PubMed ID: 21690620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.